HbA1c and clinical outcomes after endovascular treatment in patients with posterior circulation large vessel occlusion: a subgroup analysis of a nationwide registry (BASILAR)

摘要

Background and aims: Recently, several clinical trials have shown that increased glycated hemoglobin (HbA1c) level is correlated with poor clinical outcomes in ischemic stroke patients after thrombolysis and possibly after mechanical thrombectomy. However, the effect of HbA1c on posterior circulation large vessel occlusion (PCLVO) patients treated with endovascular thrombectomy (EVT) remains unclear. This multicenter study assessed the association between the HbA1c levels and clinical outcomes in patients with PCLVO after EVT. Methods: We studied 385 PCLVO ischemic stroke patients included in the EVT for acute basilar artery occlusion study (BASILAR). Patients were divided into a high HbA1c level group (HbA1c 6.5%) and a low HbA1c level group (HbA1c ?6.5%). The efficacy outcome was a 90-day favorable functional outcome (modified Rankin Scale 0–3). The safety outcomes included symptomatic intracerebral hemorrhage and mortality at 90?days after EVT. Results: The frequency of a favorable outcome in patients with an HbA1c ?6.5% was significantly higher than that in the HbA1c 6.5% group (41.2% versus 26.2%, p?=?0.001). In multivariate analysis with adjusted confounders, high HbA1c levels and favorable outcomes were significantly negatively correlated. There was also a significant association between high HbA1c levels and mortality after 3?months. The negative effects of high HbA1c levels on functional status after 3?months were exacerbated in patients aged ?65?years. Conclusion: Our multicenter study suggests that a higher serum HbA1c level (HbA1c 6.5%) is an independent predictor of a 90-day poor outcome and mortality in patients with PCLVO after EVT, particularly in those aged ?65?years. Clinical Trial Registry identifier: ChiCTR1800014759.